All News

Abstract 2687: GLP-1 RA in PsA In combined Toronto + NYU cohort, GLP-1 RA significantly associated with reduced: - Weight, CRP, and pain scores - Each 1% reduction in body weight associated w/ TJC, DAPSA, EQ-5D (QoL), LDL, Systolic BP @RheumNow #ACR25 https://t.co/30lPDkALKs

Links:

Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Biologic choice in PsA: consider factoring in obesity ⚖️ Abstract 2691: In a longitudinal cohort study, obesity associated with ↓ odds of achieving minimal disease activity (MDA) among pts on TNFi, but not with other DMARDs @RheumNow #ACR25 https://t.co/p4KaH6HKYj

Links:

Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Abstract 2690: Food as a Medicine Mediterranean vs low-calorie DASH vs control diet in PsA (multicenter RCT): 🔹 All 3 groups showed significant weight loss & DAPSA by wk 24 🔹 Weight loss not diet type may be the driver of clinical improvement @RheumNow #ACR25 https://t.co/rBS3HR1HXl

Links:

Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
In a 5-year EHR-based cohort, PsO patients initiating IL-17i had significantly lower incidence of PsA/IA vs IL-23i, IL-12/23i, or TNFi. IL-17i reduced time with PsA/IA by 45% vs IL-23i, 61% vs IL-12/23i, and 74% vs TNFi. Further research need investigate if IL-17i may delay https://t.co/0PTbXZpLbu

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
In PsA patients, GLP-1 RA therapy led to significant weight loss and improvements in CRP, pain, lipids, and blood pressure. PsA outcomes improved proportionally with weight loss. Regression analyses revealed that each 1% reduction in body weight was associated with significant https://t.co/Pph1PjfOve

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Deucravacitinib (TYK2) in PsA from POETYK trials Improved ACR20 at wk16 (NNT ~5), less benefit for ACR70 (NNT ~20) Steady improvements during open label extension (all pts received drug) Would expect approval for PsA soon... where will this fit in your approach? @RheumNow https://t.co/325h2hf0AE

Links:

Mike Putman EBRheum ( View Tweet)
#ACR25 Clinical Preview by Prof Coates for use now: GLP-1 agonist & Diet Abstr#813 GIP/GLP-1 improved MSK pain Abstr#849 GLP-1 reduced risk of #MACE in PsA Abstr#2690 RCT = the degree of weight loss regardless specific dietary strategy determined benefit in PsA @RheumNow https://t.co/4jB0fFHosC

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Does diet matter in PsA? Randomized study comparing advice, DASH low calorie, Mediterranean diet Seems that weight loss corresponds better with benefit than diet. BMI reduction remains focus in PsA Laura Coates #ACR25 meeting review @RheumNow https://t.co/CqR25sJdDc

Links:

David Liew drdavidliew ( View Tweet)
Impact on handedness in PsA disease activity and structural damage: a question that often comes in my practice Comments on Abstract #1415 presented at #ACR25 https://t.co/GilOFvXajJ @RheumNow

Links:

Aurelie Najm AurelieRheumo ( View Tweet)

#ACR25 Clinical Review by Prof Coates @DrLauraCoates to be applied tomorrow! Early Diagnosis/Tx Abstr#2689 EHR study = IL-17i could prevent #PsA vs IL-23/TNFi Abstr#576 Oligo → Polyarthritis progression in women, no DMARD, enthesitis, dactylitis, nail psoriasis @RheumNow https://t.co/e1hCERpCNW

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Clinical Year in Preview SpA: no difference in efficacy rotating vs switching bDMARD MoA for next steps @RheumNow #ACR25 #LB09 https://t.co/shCLgk7Yqz

Links:

Jiha Lee JihaRheum ( View Tweet)
Do biologics prevent PsA? Retro cohort analysis EHR through natural language processing 5 years trends PsO treated w/ IL-17i had lower incidence of PsA/IA than pts treated w/ IL-23i, IL-12/23i, or TNFi therapies Adjustment on several confounding Prospective data heavily https://t.co/W9MFaWNbWC

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
ACR25 coming to a close with Clinical Year in Preview For PsA, can biologics prevent damage? If so, which one? Difficult to answer often b/c confounding by indication. NLP-informed propensity matching beyond demographics for clinical factors like BSA @RheumNow #ACR25 A#2689 https://t.co/jjpb0kTo34

Links:

Jiha Lee JihaRheum ( View Tweet)
#YearInPreview at #ACR25 @DrLauraCoates introduces the session with a teaser for work that will be presented later today. Are we entering an era in which we will be able to prevent #PsA? Find out more at 12:00 today, Abs #2689 @RheumNow https://t.co/GDTBGNTCCd

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
The DIPSA study: can diet improve PsA? Finally a RCT, and the general message is Loose weight, regardless of the diet! 3 arms: -Mediterranean diet 31pts -Low-calorie Dietary Approaches (DASH-LC) 30pts -Standard of care 31pts Primary outcome change in DAPSA wk 12 DASH-LC https://t.co/XH9Xdn0g96

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
#ACR25 Abstr#LB20 At EULAR, data for Phase 3 RCT of Deucravacitinib, Tyk2-i in active #PsA showed ACR20 was met at WK16. Here, data showed sustained response through WK 52 across core domains inc. those who switched PBO->DEU. No major safety assoc. with JAK-i.A few acne @RheumNow https://t.co/tmzQMOtjev

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
POETYK PsA-1 (one of paired deucravacitinib in PsA ph3 registration studies) Oral med Good outcomes Safety very good but the bar is very high nowadays in PsA Questions splicing through depth of response Definitely will find a place in therapy, but where? #ACR25 LB19 @RheumNow https://t.co/iqmHQrMTYN

Links:

David Liew drdavidliew ( View Tweet)
POETYK PsA 1 and 2 Deucravacitinib TYK2 inhibitor Ph3 RCT 52 wks data Deucra 336pts PBO 334pts then crossover wk 16 to 52 Pooled analysis wk 16 ACR 20 54% vs. 31% Enthesitis reduction LEI 52% vs. 45% Dactylics resolution 58% vs. 44% POETYK-PsA 1 Wk 52 ACR 20 63% ACR50 44% PASI https://t.co/LYJbU8fYwI

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
In POETYK PsA-1, deucravacitinib showed sustained efficacy through Week 52 in PsA, improving joint, skin, PROs, and radiographic progression. Safety remained favorable with no new signals. TYK2 inhibition continues to show promise. Abstract#LB20 @RheumNow #ACR25 https://t.co/sGkk062HqJ

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Mease et al. 52 week results deucravacitinib in PsA. Approx ACR20 60%, ACR50 40%, ACR70 25%. Sustained radiographic benefit. No new safety signals @RheumNow #ACR25 Abstr#LB20 https://t.co/vKqjb08mI8

Links:

Richard Conway RichardPAConway ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×